| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $81.4M | +144.6% |
| R&D Expense | $129.6M | +8.5% |
| SG&A Expense | $52.9M | -2.4% |
| Operating Income | -$106.0M | +35.5% |
| Interest Expense | $12.2M | -8.1% |
| Pre-tax Income | -$114.2M | +22.7% |
| Income Tax | $0 | — |
| Net Income | -$114.2M | +22.7% |
| EPS (Basic) | -$1.42 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $65.9M | -36.4% |
| Accounts Receivable | $3.0M | +324.3% |
| Inventory | $385K | +0.0% |
| Current Assets | $91.8M | -25.7% |
| Total Assets | $244.4M | -9.4% |
| Current Liabilities | $122.6M | +101.6% |
| Total Liabilities | $250.2M | +23.9% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$46.4M | +55.6% |
| Capital Expenditures | $3.8M | -22.8% |
| Investing Cash Flow | -$4.1M | -117.5% |
| Financing Cash Flow | $12.3M | -77.5% |
| Free Cash Flow | -$50.2M | +54.1% |
| +33.0% |
| EPS (Diluted) | -$1.42 | +33.0% |
| Stockholders' Equity |
| -$5.8M |
| -108.5% |